Abstract
α1 -Acid glycoprotein (AGP) is a heavily glycosylated serum glycoprotein containing five complex-type N-linked glycans (Fig. 1) [1,2]. It is a positive acute-phase glycoprotein of which the plasma level will increase 2-6-fold under acute (e.g. trauma, burns, bacterial infections) or chronic inflammatory conditions (e.g. rheumatoid arthritis (RA)) as a result of the hepatic acute-phase reaction. Its exact function is not known yet, although drug- and steroid-binding activities have been described [3,4], but also a number of immunomodulating activities [5–8]. The latter activities have appeared to depend on the carbohydrate moiety of the molecule. At least 12 glycoforms of AGP can be detected in normal serum [9]. They differ in degree of branching (di-antennary versus tri- or tetraantennary glycans) as well as in degree of fucosylation and sialylation of the glycans. Formerly, it was assumed that the occurrence of these glycoforms resulted from a non-specific heterogeneity in the glycosylation process of AGP during its biosynthesis in the liver. However, in the last decade this view has changed, because it has become clear that the relative occurrence of the AGP glycoforms in plasma is strongly dependent on the (patho) physiological condition. For example, acute inflammation induces transient time-dependent increases in the level of diantennary containing glycoforms, coinciding partially with abundant increases of strongly fucosylated glycoforms of AGP [10]. Inflammatory cytokines and hormones are involved in the regulation of these changes by an, as yet, unknown effect on the glycosylation process in the liver [11]. This knowledge has become available owing to the technique developed by Bøg-Hansen [12] of crossed affmo-immunoelectrophoresis (CAIE) of sera or cell culture media with lectins as affino-component in the first dimension gel.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Schmid, K., Nimberg, R.B., Kimura, A., Yamaguchi, H., and Binette, J.P., 1977, The carbohydrate units of human plasma α1-acid glycoprotein, Biochim. Biophys. Acta 492:291–302.
Voshima, H., Matsumoto, A., Mizuochi, T., Kawasaki, T., and Kobata, A., 1981, Comparative study of the carbohydrate moieties of rat and human plasma α1-acid glycoproteins, J. Biol. Chem. 256:8476–8484.
Imamura, H., Maruyama, T., Okabe, H., Shimada, H., and Otagiri, M., 1994, A simple and rapid fluorometric determination method of α1-acid glycoprotein in serum using quinaldine red, Pharmaceut. Res. 11:566–570.
Szallasi, A., Lewin, N.E., and Blumberg, P.M., 1992, Identification of α1-acid glycoprotein (orosomucoid) as a major vanilloid binding protein in serum, J. Pharm. Exp. Therap. 262:863–888.
Bennett, M., and Schmid, K., 1980, Immunosuppression by human plasma α1-acid glycoprotein: Importance of the carbohydrate moiety, Proc. Natl. Acad. Sci. U.S. 77, 6109–6113.
Pos, O., Oostendorp, R.A.J., Van der Stelt, M.E., Scheper, R.J., and Van Dijk, W., 1990, Con A-nonreactive human α1-acid glycoprotein (AGP) is more effective in modulation of lymphocyte proliferation than Con A-reactive AGP serum variants, Inflammation 14, 133–141.
Bories, P.N., Feger, J., Benbernou, N., Rouzeau, J.-D., Agneray, J., and Durand, G., 1990, Prevalence of tri-and tetraantennary glycans of human α1-acid glycoprotein in release of macrophage inhibitor of interleukin-1 activity, Inflammation 14:315–323.
Boutten, A., Dehoux, M., Deschenes, M., Rouzeau, J.-D., Bories, P.N., and Durand, G., 1992, α1-Acid glycoprotein potentiates lipopolysaccharide-induced secretion of interleukin-1β, interleukin-6 and tumor necrosis factor-α by human monocytes and alveolar and peritoneal macrophages, Eur. J. Immunol. 22:2687–2695.
Van der Linden, E.C.M., De Graaf, T.W., Anbergen, M.G., Dekker, R.M., Van Ommen, E.C.R., Van de Eijnden, D.H., and Van Dijk, W., 1994, Preparative affinity electrophoresis of different glycoforms of serum glycoproteins: Application for the study of inflammation-induced expression of sialyl-Lewisx groups on α1-acid glycoprotein (orosomucoid). (1994) Glycosyl. Disease 1:45–52.
De Graaf, T.W., Van der Stelt, M.E., Anbergen, M.G., and Van Dijk, W., 1993, Inflammation-induced expression of sialyl Lewis X-containing glycan structures on α1-acid glycoprotein (orosomucoid) in human sera, J. Exp. Med. 177, 657–666.
Van Dijk, W., Turner, G.A., and Mackiewicz, A., 1994, Changes in glycosylation of acute-phase proteins in health and disease: occurrence, regulation and function, Glycosyl. Disease 1:5–14.
Heegaard, P.M.H., Heegaard, N.H.H., and Bøg-Hansen, T.C., 1992, Affinity electrophoresis for the characterization of glycoproteins. The use of lectins in combination with immunoelectrophoresis. In: Affinity electrophoresis: Principles and application (Breborowicz, J. and Mackiewicz, A., eds.), CRC Press, Boca Raton, Chapter 1, p. 3–21.
Takeo, K., 1984, Affinity electrophoresis: Principles and applications, Electrophoresis 5:187–195.
Bierhuizen, M.F.A, De Wit, M., Govers, C.A.R.L., Koeleman, C., Pos, O., and Van Dijk, W., 1988, Glycosylation of three molecular forms of human α1-acid glycoprotein having different interactions with concanavalin A. Variations in the occurrence of di-, tri-, and tetraantennary glycans and the degree of sialylation, Eur. J. Biochem. 175:387–394.
Van der Linden, E.C.M., and Van Dijk, W. 1994, Changes in glycosylation of α1-acid glycoprotein (AGP) during trauma and sepsis, Abstr. 3rd Jenner Glycoirnmunol. Meet, II Ciocco, Italy, 11–14 October, Glycosyl. Disease 1(3):216.
De Graaf, T.W., Van Ommen, E.C.R., Van der Stelt, M.E., Kerstens, P.J.S.M., Boerbooms, A.M.Th., and Van Dijk, W., 1994, Effects of low-dose methotrexate therapy on the concentration and the glycosylationof α1-acid glycoprotein in the serum of rheumatoid arthritis patients: A longitudinal study, J. Rheumatol. 21(12):2216.
Treuheit, M., and Halsall, H.B., 1991, HPLC of individual site glycoforms in serum orosomucoid, Chromatographia 31:478–480.
Pos, O., Van Dijk, W., Ladiges, N., Linthorst, C., Sala, M., Van Tiel, D., and Boers, W., 1988, Glycosylation of four acute-phase glycoproteins secreted by rat liver cells in vivo and in vitro. Effects of inflammation and dexamethasone, Eur. J. Cell Biol. 46:121–128.
Mackiewicz, A., Dewey, M.J., Berger, F.C., and Baumann, EL, 1991, Acute-phase mediated change in glycosylation of rat α1-acid glycoprotein in transgenic mice, Glycobiology 1:265–269.
Drechou, A., Perez-Gonzalez, N., Agneray, J., Feger, J., and Durand, G., 1989, Increased affinity to concanavalin A and enhanced secretion of alpha 1-acid glycoprotein by hepatocytes isolated from turpentine-treated rats. Eur. J. Cell Biol. 50:111–116.
Pos, O., Moshage, H.J., Yap, S.-H., Snieders, J.P.M., Aarden, L.A., Van Gool, J., Boers, W., Brugman, A.M., and Van Dijk, W., 1989, Effects of monocytic products, recombinant interleukin-1 and recombinant interleukin-6 on the glycosylation of α1-acid glycoprotein: studies with primary human hepatocyte cultures and rats. Inflammation. 13:415–424.
Mackiewicz, A., and Kushner, I., 1990, Transforming growth factor β1 influences glycosylation of α1-protease inhibitor in human hepatoma cell lines, Inflammation 14:485–487.
Varki, A., 1994, Selectin ligands, Proc. Natl. Acad. Sci. U.S. 91:7390–7397.
Corkill, M.E., Kirkham, B.W., Haskard, D.O., Barbatis, C., Gibson, T., and Panayi, G.S., 1991, Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion molecule, J. Rheumatol. 18:1453–1460.
Walz, G., Aruffo, A., Kolanus, W., Bevilacqua, M., and Seed, B., 1990, Recognition by ELAM-1 of the sialyl-LeX determinant on myeloid and tumor cells. Science 250, 1132–1134.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
van Dijk, W. (1995). α1-Acid Glycoprotein. In: Alavi, A., Axford, J.S. (eds) Glycoimmunology. Advances in Experimental Medicine and Biology, vol 376. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1885-3_24
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1885-3_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5768-1
Online ISBN: 978-1-4615-1885-3
eBook Packages: Springer Book Archive